Minapharm is an expert in the field of biopharmaceuticals, and it has three subsidiaries that specialize in different aspects of this field: MiGenTra Egypt produces therapeutic recombinant proteins and viral vectors, ProBioGen AG focuses on cell line engineering and proprietary technologies, and MiGenTra GmbH provides cell and gene-based therapies in Africa and the Middle East.
Established in 2001, MiGenTra Egypt is Minapharm’s first subsidiary. Originally a joint-venture between German-based Rhein-Biotech (now Dynavax Europe) and Minapharm Pharmaceuticals, MiGenTra Egypt specializes in the process development and drug substance manufacturing of therapeutic recombinant proteins and viral vectors. The company now has 10 self-developed biopharmaceutical products as well as a large pipeline of immunotherapeutic recombinant products primarily focused on liver disease, thrombosis and haemostasis, infertility, oncology, and rheumatoid arthritis.
Learn moreProBioGen, an internationally renowned and experienced CDMO and technology provider, has been a Berlin-based subsidiary of Minapharm since 2010. With its offer of intelligent biopharmaceutical solutions for the biotech industry at large, ProBioGen is specialized in cell line engineering and innovative proprietary technologies. The company has more than 25 years of experience.
Learn more
Established in 2021 by Minapharm and our Berlin-based subsidiary ProBioGen, MiGenTra GmbH works together with clinical centers of excellence to satisfy the unmet medical needs of patients in Africa and the Middle East. With its access to a cutting-edge, large-scale, end-to-end manufacturing facility in Cairo, MiGenTra relies on local production to capitalize on its scientific, regulatory, market-access expertise, and ideal geographic location to provide innovative cell and gene-based therapies at affordable prices.
Learn more
